Indivior AG真人官方 World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
Indivior (Nasdaq/LSE: INDV) has released results from a significant real-world study showing that their extended-release buprenorphine (BUP-XR) treatment demonstrated superior outcomes for opioid use disorder (OUD) patients. The study, published in Drug and Alcohol Dependence Reports, revealed that BUP-XR patients had 57% lower odds of emergency department visits compared to those without medication treatment.
Key findings show that BUP-XR patients experienced significantly lower hospitalization rates (3% vs 5% for daily oral treatment) and notably reduced inpatient costs - nearly five times lower than daily oral buprenorphine patients and ten times lower than untreated patients. Importantly, no opioid overdose-related ED visits were recorded in the BUP-XR group during the six-month study period, compared to 1.2% and 1% overdose rates in other groups.
Indivior (Nasdaq/LSE: INDV) ha pubblicato i risultati di uno studio significativo nel mondo reale, che dimostra come il loro trattamento con buprenorfina a rilascio prolungato (BUP-XR) abbia mostrato risultati migliori per i pazienti con disturbo da uso di oppioidi (OUD). Lo studio, pubblicato su Drug and Alcohol Dependence Reports, ha evidenziato che i pazienti trattati con BUP-XR avevano una probabilit脿 inferiore del 57% di visite al pronto soccorso rispetto a coloro che non ricevevano alcun trattamento farmacologico.
I risultati chiave mostrano che i pazienti con BUP-XR hanno sperimentato tassi di ospedalizzazione significativamente pi霉 bassi (3% contro il 5% per il trattamento orale giornaliero) e costi di ricovero notevolmente ridotti - quasi cinque volte inferiori rispetto ai pazienti con buprenorfina orale giornaliera e dieci volte inferiori rispetto ai pazienti non trattati. 脠 importante sottolineare che nel gruppo BUP-XR non sono state registrate visite al pronto soccorso correlate a sovradosaggio da oppioidi durante il periodo di studio di sei mesi, a differenza dei tassi di sovradosaggio dell'1,2% e dell'1% negli altri gruppi.
Indivior (Nasdaq/LSE: INDV) ha publicado los resultados de un estudio significativo en condiciones reales que muestra que su tratamiento con buprenorfina de liberaci贸n prolongada (BUP-XR) demostr贸 mejores resultados para pacientes con trastorno por uso de opioides (OUD). El estudio, publicado en Drug and Alcohol Dependence Reports, revel贸 que los pacientes tratados con BUP-XR ten铆an un 57% menos de probabilidades de acudir a urgencias en comparaci贸n con aquellos sin tratamiento farmacol贸gico.
Los hallazgos clave muestran que los pacientes con BUP-XR experimentaron tasas de hospitalizaci贸n significativamente m谩s bajas (3% frente al 5% del tratamiento oral diario) y costos hospitalarios notablemente reducidos: casi cinco veces menores que los pacientes con buprenorfina oral diaria y diez veces menores que los pacientes no tratados. Es importante destacar que en el grupo BUP-XR no se registraron visitas a urgencias relacionadas con sobredosis de opioides durante el per铆odo de estudio de seis meses, en comparaci贸n con tasas de sobredosis del 1,2% y 1% en otros grupos.
Indivior (Nasdaq/LSE: INDV)電� 鞁れ牅 頇橁步鞐愳劀 歆勴枆霅� 欷戩殧頃� 鞐瓣惮 瓴瓣臣毳� 氚滍憸頄堨姷雼堧嫟. 鞚� 鞐瓣惮電� 攴鸽摛鞚� 鞛リ赴 歆�靻嶍槙 攵�頂勲爤雲鸽ゴ頃�(BUP-XR) 旃橂臧� 鞓ろ敿鞓れ澊霌� 靷毄 鞛レ暊(OUD) 頇橃瀽霌れ棎瓴� 鞖办垬頃� 瓴瓣臣毳� 雮橅儉雰堨潓鞚� 氤挫棳欷嶋媹雼�. Drug and Alcohol Dependence Reports鞐� 瓴岇灛霅� 鞐瓣惮鞐� 霐半ゴ氅�, BUP-XR 旃橂毳� 氚涭潃 頇橃瀽霌れ潃 鞎诫 旃橂毳� 氚涭 鞎婌潃 頇橃瀽霌れ棎 牍勴暣 鞚戧笁鞁� 氚╇ 臧�電レ劚鞚� 57% 雮晿雼�瓿� 氚濏榾臁岇姷雼堧嫟.
欤检殧 瓴瓣臣搿滊姅 BUP-XR 頇橃瀽霌れ澊 鞛呾洂鞙澊 順勳爛頌� 雮晿雼�(鞚检澕 瓴疥惮 旃橂甑� 5% 雽�牍� 3%)電� 鞝愱臣 鞛呾洂 牍勳毄鞚� 韥矊 臧愳唽頄堨溂氅�, 鞚措姅 鞚检澕 瓴疥惮 攵�頂勲爤雲鸽ゴ頃� 頇橃瀽 雽�牍� 瓯办潣 5氚� 雮碃 旃橂氚涭 鞎婌潃 頇橃瀽 雽�牍� 10氚� 雮晿雼�電� 鞝愳瀰雼堧嫟. 韸鬼瀳, 6臧滌洈 鞐瓣惮 旮瓣皠 霃欖晥 BUP-XR 攴鸽９鞐愳劀電� 鞓ろ敿鞓れ澊霌� 瓿茧嫟氤奠毄 甏�霠� 鞚戧笁鞁� 氚╇鞚� 鞝勴榾 鞐嗢棃鞙茧┌, 雼るジ 攴鸽９鞐愳劀電� 臧侁皝 1.2%鞕� 1%鞚� 瓿茧嫟氤奠毄 牍勳湪鞚� 氤搓碃霅橃棃鞀惦媹雼�.
Indivior (Nasdaq/LSE : INDV) a publi茅 les r茅sultats d'une 茅tude importante en conditions r茅elles montrant que leur traitement par bupr茅norphine 脿 lib茅ration prolong茅e (BUP-XR) a donn茅 des r茅sultats sup茅rieurs chez les patients souffrant de trouble li茅 脿 l'usage d'opio茂des (OUD). L'茅tude, publi茅e dans Drug and Alcohol Dependence Reports, a r茅v茅l茅 que les patients sous BUP-XR avaient 57 % moins de chances de se rendre aux urgences comparativement 脿 ceux sans traitement m茅dicamenteux.
Les r茅sultats cl茅s montrent que les patients sous BUP-XR ont connu des taux d'hospitalisation significativement plus faibles (3 % contre 5 % pour le traitement oral quotidien) et des co没ts d'hospitalisation nettement r茅duits - presque cinq fois inf茅rieurs 脿 ceux des patients sous bupr茅norphine orale quotidienne et dix fois inf茅rieurs 脿 ceux des patients non trait茅s. Il est important de souligner qu'aucune visite aux urgences li茅e 脿 une surdose d'opio茂des n'a 茅t茅 enregistr茅e dans le groupe BUP-XR pendant la p茅riode d'茅tude de six mois, contre des taux de surdose de 1,2 % et 1 % dans les autres groupes.
Indivior (Nasdaq/LSE: INDV) hat Ergebnisse aus einer bedeutenden AG真人官方-World-Studie ver枚ffentlicht, die zeigt, dass ihre langwirksame Buprenorphin-Behandlung (BUP-XR) 眉berlegene Ergebnisse bei Patienten mit Opioidgebrauchsst枚rung (OUD) erzielt. Die Studie, ver枚ffentlicht in Drug and Alcohol Dependence Reports, zeigte, dass BUP-XR-Patienten 57 % geringere Chancen auf Notaufnahmebesuche hatten als Patienten ohne medikament枚se Behandlung.
Wesentliche Ergebnisse zeigen, dass BUP-XR-Patienten signifikant niedrigere Hospitalisierungsraten aufwiesen (3 % gegen眉ber 5 % bei t盲glicher oraler Behandlung) und deutlich reduzierte station盲re Kosten 鈥� fast f眉nfmal niedriger als bei Patienten mit t盲glicher oraler Buprenorphin-Behandlung und zehnmal niedriger als bei unbehandelten Patienten. Wichtig ist, dass in der BUP-XR-Gruppe w盲hrend des sechsmonatigen Studienzeitraums keine Notaufnahmebesuche aufgrund von Opioid-脺berdosierungen verzeichnet wurden, im Vergleich zu 脺berdosierungsraten von 1,2 % und 1 % in den anderen Gruppen.
- BUP-XR treatment showed 57% lower odds of emergency department visits compared to no medication treatment
- No opioid overdose-related ED visits recorded in BUP-XR cohort vs 1-1.2% in other groups
- Inpatient costs were 5x lower compared to daily oral treatment and 10x lower than no treatment
- Lower hospitalization rates for BUP-XR patients (3%) versus daily oral treatment (5%)
- BUP-XR cohort had significantly higher overall costs compared to daily oral treatment due to higher pharmacy costs
- Study limited by six-month observation window and may not represent uninsured populations
Insights
Indivior's study shows BUP-XR reduces healthcare utilization and costs versus alternatives, potentially strengthening market position despite higher pharmacy costs.
Indivior's newly published real-world evidence demonstrates significant healthcare utilization advantages for their extended-release buprenorphine (BUP-XR) formulation in treating opioid use disorder (OUD). The data shows patients receiving BUP-XR experienced
The hospitalization metrics are particularly compelling from a healthcare economics perspective. Only
The absence of any opioid overdose-related ED visits in the BUP-XR cohort (versus
However, the economic picture has important nuances. Despite lower emergency and inpatient utilization, BUP-XR's overall costs were similar to no treatment and higher than daily oral therapy 鈥� primarily driven by higher pharmacy expenses. The study doesn't clarify whether these higher pharmacy costs stem directly from BUP-XR's pricing or other medications, which creates some uncertainty about the total value proposition.
For Indivior, these findings provide robust clinical and economic evidence to support market access discussions and potentially drive increased adoption of their BUP-XR product, particularly in healthcare systems prioritizing reduced emergency utilization and hospitalization costs.
- Extended-release听buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician听o铿僣e听visits听compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD)
- The study indicates听BUP-XR may be an important tool in reducing ED visits, improving healthcare resource utilization and patient outcomes
搁滨颁贬惭翱狈顿,听痴补., July 23, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports, which examined demographic and clinical factors associated with ED visits among adults diagnosed with听opioid use disorder (OUD) over a six-month follow-up period.
The听study found听that听patients treated听with听BUP-XR, in听the听form听of听the听once-monthly听long-acting injectable听formulation听of听buprenorphine, had
"Opioid听overdose-related听ED听visits听are听a听critical concern听in听the听ongoing听opioid epidemic," said Christian听Heidbreder,听Ph.D., Chief Scienti铿乧听O铿僣er at Indivior. "These 铿乶dings underscore the clinical and economic value of long-acting injectable treatments of听OUD. By reducing ED and physician o铿僣e visits, BUP-XR may help ease the burden on our healthcare system while supporting long-term recovery outcomes for patients."
The Indivior-funded study also revealed that patients treated with BUP-XR incurred lower inpatient healthcare costs. Inpatient costs for this group were nearly 铿乿e听times听lower听compared to patients receiving daily oral buprenorphine, and more than 10 times lower compared to patients receiving no MOUD. The BUP-XR cohort did have similar overall all-cause costs compared to the no MOUD cohort and had signi铿乧antly higher overall costs compared to the daily oral buprenorphine cohort; this was primarily driven by higher outpatient pharmacy costs in the BUP-XR cohort, although it was not possible to determine if the BUP-XR medication itself was driving the di铿�erence.
Hospitalization rates for BUP-XR were similarly lower: only
These 铿乶dings are based on observed claims data and re铿俥ct healthcare utilization during the de铿乶ed study period. Although the results o铿�er valuable insights for public health o铿僣ials, emergency care providers, and policymakers, the study sample may not fully represent all individuals with OUD, particularly those who are uninsured or outside traditional healthcare systems. Additionally, the six-month observation window may not capture long-term treatment engagement or relapse risk.
罢丑别听蹿耻濒濒听蝉迟耻诲测听颈蝉听补惫补颈濒补产濒别听丑别谤别:
Disclosure:
This听press release听has听been听issued听by听Indivior Inc. and the content has not been approved or authorized by the College on Problems of Drug Dependence.
About听SUBLOCADE庐
SUBLOCADE庐 (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION
INDICATION
SUBLOCADE听is听indicated听for听the听treatment of听moderate听to听severe听opioid听use听disorder in听patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
SUBLOCADE should be used as part of a complete treatment plan that includes counseling and听psychosocial听support.
HIGHLIGHTED听SAFETY听INFORMATION
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY
- Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body 铿倁ids and may cause occlusion, local tissue damage,听and听thrombo-embolic听events, including听life-threatening听pulmonary emboli,听if administered intravenously.
- Because of the risk of serious harm or death that could result from intravenous self- administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certi铿乪d in this program and comply with the REMS requirements.
CONTRAINDICATIONS
Hypersensitivity听to听buprenorphine听or听any听other ingredients听in听SUBLOCADE.
WARNINGS听AND听PRECAUTIONS
Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions听indicative听of听diversion听or听progression听of听opioid dependence and addictive behaviors.
Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of听benzodiazepines or other CNS depressants while under treatment with SUBLOCADE.
Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis.
Neonatal听Opioid Withdrawal听Syndrome:听Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during听pregnancy.
Adrenal听Insu铿僣iency:听If听diagnosed,听treat听with听physiologic听replacement听of听corticosteroids,听and wean patient o铿� of the opioid.
Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately.
Risk听of听Hepatitis,听Hepatic Events:听Monitor听liver function听tests听prior to听and听during听treatment.
Risk听of听Withdrawal听in听Patients听Dependent听on听Full听Agonist Opioids:听Verify听that听patients听have tolerated transmucosal buprenorphine before injecting SUBLOCADE.
Treatment听of听Emergent听Acute听Pain:听Treat听pain听with听a听non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic听e铿�ect.
ADVERSE听REACTIONS
Adverse reactions commonly associated with SUBLOCADE (in 鈮�
For听more听information听about SUBLOCADE,听the听full听Prescribing听information听including听BOXED WARNING, and Medication Guide, visit
About听Opioid Use听Disorder听(OUD)
Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences.听OUD may听a铿�ect听the听parts听of听the听brain听that听are necessary for life-sustaining functions.
About听Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing听medicines听to听treat听opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for听OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease.
Building听on听its听global portfolio听of听OUD听treatments,听Indivior has听a听pipeline听of听product candidates designed to expand on its heritage in this category. Headquartered in
View original content to download multimedia:
SOURCE Indivior PLC
FAQ
What were the key findings of Indivior's (INDV) real-world study on BUP-XR treatment?
How did hospitalization rates compare between BUP-XR and daily oral treatment in Indivior's study?
What were the overdose rates among different treatment groups in INDV's study?
What were the cost implications of BUP-XR treatment compared to other options?
What are the limitations of Indivior's BUP-XR study?
